Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa

Area of Science:

• Dermatopathology
• Oncology
• Immunohistochemistry

Background:

• Differentiating dermatofibroma (DF) from dermatofibrosarcoma protuberans (DFSP) is clinically challenging.
• Current markers like CD34 and Factor XIIIa show overlapping expression patterns, limiting their diagnostic specificity.
• Tenascin, an extracellular matrix glycoprotein, plays roles in carcinogenesis and wound healing, suggesting potential diagnostic utility.

Purpose of the Study:

• To evaluate the diagnostic role of tenascin in distinguishing DF from DFSP.
• To compare the expression of tenascin with CD34 and Factor XIIIa in DF and DFSP.
• To identify reliable immunohistochemical markers for accurate tumor classification.

Main Methods:

• Immunohistochemical staining was performed on 20 cases each of DFSP and DF.
• Antibodies used included tenascin, CD34, and Factor XIIIa, employing the streptavidin biotin technique.
• Expression levels were assessed within the tumors and at the dermal-epidermal junction.

Main Results:

• Tenascin showed strong positivity at the dermal-epidermal junction in 100% of DF cases, but was negative in DFSP.
• Tenascin was expressed within the lesion in 80% of both DF and DFSP cases.
• CD34 and Factor XIIIa exhibited overlapping expression, with CD34 more frequent in DFSP and Factor XIIIa in DF.

Conclusions:

• Increased tenascin expression at the dermal-epidermal junction is a highly specific marker for differentiating DF from DFSP.
• Tenascin expression within the tumor lesion lacks specificity for distinguishing between DF and DFSP.
• This tenascin-based approach offers improved diagnostic accuracy compared to CD34 and Factor XIIIa.